SCHEMBL13005605

SCHEMBL13005605

CC(C)Cc1cccc(CN(Cc2ccccc2)C(C)CN(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.45
HTR2A P28223 3/20 0.45
SLC6A3 Q01959 3/20 0.45
ADRA2B P18089 2/20 0.45
ADRA2C P18825 2/20 0.45
ADRA1A P35348 2/20 0.45
KCNH2 Q12809 2/20 0.45
SLC6A4 P31645 2/20 0.45
OPRK1 P41145 1/20 0.45
SIGMAR1 Q99720 4/20 0.42
CETP P11597 1/20 0.42
ALDH1A1 P00352 2/20 0.42
TSHR P16473 2/20 0.42
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13005512 0.86 CETP (0.41) SLC6A2HTR2ASLC6A3ADRA2BADRA2C
SCHEMBL13005495 0.86 OPRK1 (0.43) SLC6A2HTR2ASLC6A3ADRA2BADRA2C
SCHEMBL13005518 0.85 CETP (0.40) SLC6A2HTR2ASLC6A3ADRA2BADRA2C
SCHEMBL13061024 0.84 TAAR1 (0.44) SLC6A2HTR2ASLC6A3ADRA2BADRA2C
SCHEMBL13005557 0.82 SIGMAR1 (0.41) SLC6A2HTR2ASLC6A3ADRA2BADRA2C
SCHEMBL13005515 0.81 CETP (0.40) SLC6A2HTR2ASLC6A3ADRA2BADRA2C
SCHEMBL16640979 0.79 ALDH1A1 (0.50) SLC6A2HTR2ASLC6A3ADRA2BADRA2C
SCHEMBL13005484 0.78 OPRK1 (0.47) SLC6A2HTR2ASLC6A3ADRA2BADRA2C
SCHEMBL13005440 0.78 CALM1 (0.59) SLC6A2HTR2ASLC6A3ADRA2BADRA2C
SCHEMBL13005554 0.76 OPRD1 (0.53) SLC6A2HTR2ASLC6A3ADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed